Home/Pipeline/Huntington's Program

Huntington's Program

Huntington's Disease

Pre-clinicalActive

Key Facts

Indication

Huntington's Disease

Phase

Pre-clinical

Status

Active

Company

reMYND

About reMYND

reMYND is a private, clinical-stage biotech developing novel oral therapeutics targeting synaptic and neuronal dysfunction in Alzheimer's and Huntington's disease. Its lead asset, REM392, is an oral small molecule designed to restore calcium homeostasis to provide both symptomatic and disease-modifying benefits in Alzheimer's. The company leverages a dual-strategy business model, combining internal drug development with a revenue-generating CRO service that validates its scientific platform and funds R&D.

View full company profile

Therapeutic Areas

Alzheimer's Disease Huntington's Disease Amyotrophic Lateral Sclerosis (ALS)

Other Huntington's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
Huntington's Disease Program	Rumi Scientific	Pre-clinical	Active
SOM3355	SOM Biotech	Phase 3	Active
LETI-101	ElevateBio	Preclinical	Active
Somatic Expansion Inhibitor Program	LoQus23 Therapeutics	Preclinical	Active
Preclinical Program	Excision BioTherapeutics	Preclinical	Active
NA-841	Biomed	Phase 2A	Active
T3D-959 (Future)	T3D Therapeutics	Pre-clinical / Research	Active
HD mAb Therapy	HD Immune	Pre-clinical	Active
TT-P34	Teitur Trophics	Pre-clinical	Active
INT41	Vybion	Pre-clinical	Active
Pridopidine	Prilenia Therapeutics	Phase 3	Active